{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:02:18Z","timestamp":1648771338208},"reference-count":39,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,31]],"date-time":"2016-12-31T00:00:00Z","timestamp":1483142400000},"content-version":"vor","delay-in-days":1582,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurolog\u00eda"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.nrl.2011.09.008","type":"journal-article","created":{"date-parts":[[2011,11,10]],"date-time":"2011-11-10T19:37:22Z","timestamp":1320953842000},"page":"432-441","source":"Crossref","is-referenced-by-count":5,"title":["Consenso espa\u00f1ol sobre la utilizaci\u00f3n de natalizumab (Tysabri\u00ae) - 2011"],"prefix":"10.1016","volume":"27","author":[{"given":"O.","family":"Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Garc\u00eda-Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Arroyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"\u00c1lvarez-Cerme\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Arbizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Izquierdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Saiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"J.Olascoaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rodr\u00edguez-Antig\u00fcedad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Oreja-Guevara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Montalb\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrl.2011.09.008_bib0005","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrl.2011.09.008_bib0010","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrl.2011.09.008_bib0015","unstructured":"Ficha T\u00e9cnica Tysabri Junio de 2011."},{"key":"10.1016\/j.nrl.2011.09.008_bib0020","unstructured":"Informaci\u00f3n para el m\u00e9dico y directrices para el manejo de pacientes con esclerosis m\u00faltiple en tratamiento con Tysabri.Versi\u00f3n 8. Diciembre 2010."},{"key":"10.1016\/j.nrl.2011.09.008_bib0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/0197-2456(94)90026-4","article-title":"New Proposal for Benefit-less-risk Analysis in Clinical Trials","volume":"15","author":"Chuang-Stein","year":"1994","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.nrl.2011.09.008_bib0030","doi-asserted-by":"crossref","unstructured":"Methods and Examples for Assessing Benefit\/Risk and Safety for New Drug Applications, Proceedings of a DIA Workshop, Drug Information Journal, 1993; 27:1011-1049.","DOI":"10.1177\/009286159302700412"},{"key":"10.1016\/j.nrl.2011.09.008_bib0035","unstructured":"Benefit, Risk and Cost Management of Drugs Report of the CPHA National Advisory Panel on Risk\/Benefit Management of Drugs. Canadian Public Health Association, January 1993."},{"key":"10.1016\/j.nrl.2011.09.008_bib0040","unstructured":"Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals Report of CIOMS Working Group IV (Council for International Organizations of Medical Sciences). ISBN 92 9036 068 2. Geneva 1998."},{"key":"10.1016\/j.nrl.2011.09.008_bib0045","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/bmj.319.7212.753","article-title":"Towards a feasible model for shared decision making: focus group study with general practice registrars","volume":"319","author":"Elwim","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.nrl.2011.09.008_bib0050","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/1352458510385507","article-title":"The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study","volume":"17","author":"Fern\u00e1ndez","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.nrl.2011.09.008_bib0055","first-page":"321","article-title":"An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis","volume":"52","author":"Horga","year":"2011","journal-title":"Rev Neurol"},{"key":"10.1016\/j.nrl.2011.09.008_bib0060","unstructured":"[consultado 15\/8\/2011]. Disponible en:www.tysabri.com (Prescriber information)."},{"issue":"suppl 10","key":"10.1016\/j.nrl.2011.09.008_bib0065","first-page":"S315","article-title":"Utilization and safety of natalizumab in patients with relapsing multiple sclerosis","volume":"16","author":"Bozic","year":"2010","journal-title":"Mult Scler"},{"key":"10.1016\/j.nrl.2011.09.008_bib0070","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1474-4422(07)70078-9","article-title":"Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring","volume":"6","author":"Kappos","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrl.2011.09.008_bib0075","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1056\/NEJMct071462","article-title":"Natalizumab for multiple sclerosis","volume":"356","author":"Ransohoff","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrl.2011.09.008_bib0080","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","article-title":"Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring","volume":"10","author":"Kappos","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrl.2011.09.008_bib0085","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.nrl.2010.03.006","article-title":"Spanish Neurology Society consensus document on the use of drugs in multiple sclerosis: escalating therapy","volume":"25","author":"Garc\u00eda Merino","year":"2010","journal-title":"Neurologia"},{"key":"10.1016\/j.nrl.2011.09.008_bib0090","unstructured":"Tysabri prescribing information. Cambridge, MA:Biogen Idec, Inc; 2006."},{"key":"10.1016\/j.nrl.2011.09.008_bib0095","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/1352458510385508","article-title":"Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months","volume":"17","author":"Oliver","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.nrl.2011.09.008_bib0100","series-title":"ECTRIMS","article-title":"Assessment of the incidence of anti-JCV antibodies in a cohort of natalizumab-treated patients with multiple sclerosis","author":"Gorelik","year":"2010"},{"key":"10.1016\/j.nrl.2011.09.008_bib0105","series-title":"63rd Annual Meeting of the American Academy of Neurology April 9\u201316","article-title":"Prevalence of Anti-JCV Antibodies in MS Patients Receiving or Considering Treatment with Natalizumab: Baseline Results of STRATIFY-1","author":"Bozic","year":"2011"},{"key":"10.1016\/j.nrl.2011.09.008_bib0110","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nrl.2011.09.008_bib0115","doi-asserted-by":"crossref","DOI":"10.1002\/ana.22606","article-title":"Anti-JCV antibody prevalence in MS patients: Baseline results of STRATIFY-1","author":"Bozic","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nrl.2011.09.008_bib0120","series-title":"25th Annual Meeting of the Consortium of Multiple Sclerosis Centers","article-title":"Risk of Natalizumab-Associated ProgressiveMultifocal Leukoencephalopathy. S92","author":"Sandrock","year":"2011"},{"key":"10.1016\/j.nrl.2011.09.008_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/jnp.15.1.1","article-title":"Identification of HIV-associated progressive multifocal leukoencephalopathy: magnetic resonance imaging and spectroscopy","volume":"15","author":"Hurley","year":"2003","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.nrl.2011.09.008_bib0130","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","article-title":"Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy","volume":"354","author":"Yousry","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrl.2011.09.008_bib0135","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1128\/JCM.34.12.2929-2932.1996","article-title":"Analysis of PCR as a tool for detection of JC virus DNA in cerebrospinal fluid for diagnosis of progressive multifocal leukoencephalopathy","volume":"34","author":"Hammarin","year":"1996","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.nrl.2011.09.008_bib0140","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa0904267","article-title":"Asymptomatic reactivation of JC virus in patients treated with natalizumab","volume":"361","author":"Chen","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrl.2011.09.008_bib0145","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00415-009-5444-4","article-title":"JCV detection in multiple sclerosis patients treated with natalizumab","volume":"257","author":"Sadiq","year":"2010","journal-title":"J Neurol"},{"key":"10.1016\/j.nrl.2011.09.008_bib0150","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMc0909622","article-title":"Asymptomatic reactivation of JC virus in patients treated with natalizumab","volume":"361","author":"Gorelik","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrl.2011.09.008_bib0155","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.22107","article-title":"Assessment of JC virus DNA in blood and urine from natalizumab- treated patients","volume":"68","author":"Rudick","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nrl.2011.09.008_bib0160","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S1474-4422(10)70006-5","article-title":"Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study","volume":"9","author":"Jilek","year":"2010","journal-title":"Lancet Neurol"},{"issue":"S4","key":"10.1016\/j.nrl.2011.09.008_bib0165","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1177\/1352458509347131","article-title":"Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy","volume":"15","author":"Coyle","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.nrl.2011.09.008_bib0170","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.nrl.2010.10.004","article-title":"Natalizumab para la esclerosis m\u00faltiple remitente-recurrente","volume":"26","author":"Horga","year":"2011","journal-title":"Neurologia"},{"key":"10.1016\/j.nrl.2011.09.008_bib0175","doi-asserted-by":"crossref","unstructured":"Ghezzi A, Grimaldi LM, Marrosu MG, Pozzilli C, Comi G, Bertolotto A, et al., .Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group- Italian Neurological Society. Neurol Sci On line 14 January 2011.","DOI":"10.1007\/s10072-010-0469-0"},{"key":"10.1016\/j.nrl.2011.09.008_bib0180","first-page":"34","article-title":"El virus JC y la leucoencefalopat\u00eda multifocal progresiva: implicaciones en el tratamientoactual de la esclerosis m\u00faltiple","volume":"16","author":"Fern\u00e1ndez","year":"2010","journal-title":"Rev Esp Escl Mult"},{"key":"10.1016\/j.nrl.2011.09.008_bib0185","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1212\/01.wnl.0000327341.89587.76","article-title":"Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy","volume":"72","author":"St\u00fcve","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.nrl.2011.09.008_bib0190","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s00415-011-6019-8","article-title":"Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study","volume":"258","author":"Magraner","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/j.nrl.2011.09.008_bib0195","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons learned from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol"}],"container-title":["Neurolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485311004014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485311004014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T10:39:53Z","timestamp":1593254393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213485311004014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0213485311004014"],"URL":"https:\/\/doi.org\/10.1016\/j.nrl.2011.09.008","relation":{},"ISSN":["0213-4853"],"issn-type":[{"value":"0213-4853","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}